Tech Commercialization

Celegene

Celgene seeks to deliver truly innovative and life-changing drugs for our patients. Their vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Progenics

Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to identify, target and treat cancer. Their pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095); (2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis tools. Our first commercial product, RELISTOR® (methylnaltrexone… Read More

Evelo Therapeutics

Licensee Evelo Therapeutics will advance an immunotherapy developed by University of Chicago oncologist Thomas Gajewski that employs certain gut microbes to boost the immune system’s attack on cancer cells and improve the effectiveness of anti-cancer drugs. Evelo, Gajewski, and UChicago will work together to bring this technology to the patient… Read More

Phillips 66

Dr. Luping Yu developed new chemical compounds to generate highly efficient organic photovoltaic solar cells as a source of clean energy. Dr. Yu’s compounds have reached record efficiencies compared to other material. The technology was licensed to Phillips 66 in early 2014. Stats: Principle Investigator – Luping Yu Deal Date… Read More

Everyday Learning

Each year, approximately 4.3 million students in 220,000 US classrooms use Everyday Mathematics, a comprehensive pre-K through grade 6 mathematics program developed by the University of Chicago School Mathematics Project and initially distributed by a University start-up, Everyday Learning. Stats: Principle Investigator – Max Bell and Zalman Usiskin Deal Date… Read More

Seurat Therapeutics

Seurat Therapeutics is based on years of research by Richard Kraig, MD, PhD, at the University of Chicago that targets a naturally-derived cure for migraines aimed at the root cause rather than alleviating the symptoms. Based at the Polsky Center for Entrepreneurship and Innovation’s Polsky Exchange, the team… Read More

AbbVie

AbbVie provides funding for a collaboration with UChicago that supports preclinical research, clinical trials and possible future programs at the University resulting from this partnership. The overall collaborative efforts provide University of Chicago physicians and researchers with the opportunity to participate in AbbVie-sponsored clinical trials, access to… Read More

AduroBiotech

This company is transforming lives and isn’t looking back. As pioneers in immunotherapy, Aduro Biotech is transforming lives by discovering, developing, and commercializing immunotherapies that are making big changes in the treatment of challenging diseases like cancer. Collaborating with the Polsky Center’s Technology Commercialization and… Read More

Electrochaea

UChicago licensee Electrochaea, named one of the 100 Global Cleantech companies in 2014, uses electricity generated by the sun or wind to convert water and carbon dioxide, a greenhouse gas, into methane, the chief ingredient of natural gas. Electrochaea’s technology developed by Laurens Mets, PhD and UChicago… Read More

AgileMD

Agile MD, formerly known as Agile Diagnosis, is a web, mobile, and EHR-integrated application that provides clinicians fast access to guidelines, protocols, and reference information. Thanks to AgileMD, organizations are improving the quality of care, reducing unnecessary utilization, and lowering the risk of medical error. In fact,… Read More

ExplORer Surgical

ExplORer Surgical is an interactive surgical playbook that promotes optimal teamwork in the operating room. Best practices are built into a surgeon-customized workflow for each case. Surgical activity can be tracked and adjusted as part of… Read More

ClostraBio

ClostraBio is dedicated to understanding and treating food allergies and other disease of the immune system. Founded in 2016 by Cathryn R. Nagler, PhD and Jeffrey A. Hubbell, PhD, ColstraBio is making strides in the discovery and development of new therapeutics that modulate the protective… Read More